beLAB1407 is a new multi-year partnership between some of the UK’s leading Universities, Evotec and BMS to identify exciting and novel disease modifying therapeutic targets and platforms with the goal to develop these to new spinout companies.
The partnership combines the respective strengths of:
beLAB1407 will provide funding, technology platforms and mentoring to achieve pre-clinical proof of concept for academic ground-breaking therapeutics and technologies. Projects will be sourced from across the research activities of each university, from any disease area and will include all therapeutic modalities.
To streamline and guide the selection and approval process, a drug discovery Expert in Residence (EIR) from Evotec will be embedded within each University. The EIR will provide advice and guidance to academics with relevant projects and help develop the necessary work plan and commercialisation strategy. Project funding will depend on the envisaged work-plan and can amount to up to £ 1.25m.
At the conclusion of the beLAB1407 funding, for selected projects, the beLAB1407 team will help develop the subsequent business case, build and identify the next value inflexion point and work with you to raise the necessary financing and team to create the spinout to commercialize the results generated by the funded project.